Bigger Deal Values by Splitting Indications: PDL's Experience
Executive Summary
It is one of the odder aspects of biotech life that one of the most important new ways to increase the dealmaking value of products has nothing to do with science or negotiating tactics-but sales auditing. PDL Biopharma's deals with Roche and Biogen Idec revive the notion of splitting indications among partners, a strategy apparently killed by the Amgen/J&J battle over EPO.
You may also be interested in...
Drug Delivery Heats Up
The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.
Drug Delivery Heats Up
The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.
Payback: Making Innovation Count in Uncertain Times
Pharmaceutical innovation is not generating payback, the equation for which--and the cash-flow goals--are changing radically. That means that companies must re-think innovation, based on its ability to help companies navigate the four key S-Factors of the cash curve: start-up costs, speed to market, support costs, and scale operations. Some innovations will negotiate this and generate payback; others with apparently equal potential will dawdle in a single phase, consuming cash.